Original articles
Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (PentaximTM) and monovalent hepatitis B vaccine at 6, 10 and 14 months of age in infants in South Africa
Abstract
Methods. A DTaP-IPV//PRP~T vaccine (Pentaxim™) was given at 6, 10 and 14 weeks of age to 212 infants in South Africa. Monovalent hepatitis B vaccine was given concomitantly.
Immunogenicity was assessed using seroprotection and seroconversion rates; safety was assessed by monitoring for solicited injection site and systemic adverse events, and follow-up monitoring for unsolicited adverse events and serious adverse events.
Results. Immunogenicity was high for each vaccine antigen, and similar to a reference study done in France using a similar (2, 3 and 4 months of age) administration schedule. After the third dose, 94.6% of participants had anti-PRP 0.15 g/ml. The anti-PRP geometric mean antibody titre (GMT) was 2.0 µg/ml. The seroprotection rates for diphtheria and tetanus (0.01 IU/ml), poliovirus types 1, 2 and 3 (8 1/dil U) and hepatitis B were all 100%. Anti-polio GMTs were very high, 1 453, 1 699 and 2 398 (1/dil U) for types 1, 2 and 3, respectively. The seroconversion/vaccine response rates to pertussis antigens (4-fold increase in antibody concentration) were 97.5% for PT and 83.9% for FHA.
Conclusions. The DTaP-IPV//PRP~T vaccine was highly immunogenic at 6, 10 and 14 weeks of age in infants in South Africa, was compatible with the monovalent hepatitis B vaccine, and was well tolerated.
Authors' affiliations
Shabir Ahmed Madhi, University of the Witwatersrand
Clare Cutland, University of the Witwatersrand
Stephanie Jones, University of the Witwatersrand
Michelle Groome, University of the Witwatersrand
Esteban Ortiz, Sanofi Pasteur
Full Text
PDF (160KB)Keywords
Cite this article
Article History
Date published: 2011-01-27
Article Views
Full text views: 1678
Comments on this article
*Read our policy for posting comments here